Table 1.
Study details and cohort characteristics
| Study author | Tracer 1 | Tracer 2 | PSA | GS | ADT | Treatment | Time gap (days) | Patients | Activity 1 | Activity 2 | Time scan 1 | Time scan 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cantiello 2018 [25] | 64Cu-PSMA-617 | 18F-FCH | 0.8* | NR | NR | OP, no RT | 15 | 43 | 315 | 314 | 60 | 60 |
| Dietlein 2015 [26] | 68Ga-PSMA-11 (HBED) | 18F-DCFPyl | 6.33 | NR | NR | RT/OP | 21 | 14 | 128 | 318 | 120 | 120 |
| Pernthaler 2019 [27] | 68Ga-PSMA-11 (HBED) | 18F-Fluciclovine | 14.9 | 7.7 | Yes | RT/OP | 22 | 58 | 170 | 370 | 60 | 3 |
| Witkowska 2019 [28] | 18F-PSMA-1007 | 18F-FCH | 0.77 | 7.1 | Yes | RT/OP | 54 | 40 | 296 | 248 | 95 | 87 |
| Morigi 2015 [29] | 68Ga-PSMA-11 (HBED) | 18F-FCH | 1.72 | 7 | Yes | RT/OP | 30 | 38 | 2/Kg | 3.5/Kg | 45 | 20 |
| Afshar-Oromieh 2014 [30] | 68Ga-PSMA-11 (HBED) | 18F-FCH | 11.1 | 7.4 | Yes | RT/OP | 30 | 37 | 2/Kg | 241 | 60 | 60 |
| Calais 2019 [4] | 68Ga-PSMA-11 (HBED) | 18F-Fluciclovine | 0.48 | NR | Yes | OP, no RT | 15 | 50 | 139 | 381 | 61 | 61 |
| Schwenck 2017 [31] | 68Ga-PSMA-11 (HBED) | 11C-Choline | 9.47 | 7.7 | NR | RT/OP | 1 | 103 | 166 | 625 | 60 | 5 |
| Emmett 2019 [32] | 68Ga-PSMA-11 (HBED) | 18F-FCH | 0.42* | 7.3 | Yes | RT/OP | 14 | 31 / 91 | 2/Kg | 3.6/Kg | 60 | 60 |
| Nanni 2015 [33] | 18F-Fluciclovine | 11C-Choline | 3.2 | 7.2 | Yes | RT/OP | 7 | 50 | 340 | 3.4/Kg | 3.6 | 3.5 |
| Nanni 2016 [34] | 18F-Fluciclovine | 11C-Choline | 6.99 | NR | Yes | RT/OP | 7 | 89 | 370 | 3.4/kg | 4 | 4 |
| Bluemel 2017 [35] | 68Ga-PSMA-I&T | 18F-FCH | 5.4 | NR | NR | RT/OP | NR | 125 | 311 | 133 | 60 | 60 |
NR means either not reported, or because (partially) missing data could not be calculated. PSA reported as mean, data with asterisk as median (mean not reported), GS Gleason score, ADT (yes/no patients with androgen deprivation therapy included), Cohort (RT, post-radiotherapy; OP, post-prostatectomy), time gap (time between examination 1 and 2 in days), patients (number of patients included in both arms), activity (mean activity of radiotracer 1 and 2 applied in MBq or, where not recorded, reported target dose MBq/kg), time scan 1 and scan 2 p.i. (time of scan acquisition post injection of radiotracer in minutes)